[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
3. Stefflova K, Li H, Chen J, Zheng G: Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent. Bioconjug Chem; 2007 Mar-Apr;18(2):379-88
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent.
  • We designed and synthesized a folate receptor-targeted, water-soluble, and pharmacomodulated photodynamic therapy (PDT) agent that selectively detects and destroys the targeted cancer cells while sparing normal tissue.
  • This was achieved by minimizing the normal organ uptake (e.g., liver and spleen) and by discriminating between tumors with different levels of folate receptor (FR) expression.
  • (1) pyropheophorbide a (Pyro) as an imaging and therapeutic agent, (2) peptide sequence as a stable linker and modulator improving the delivery efficiency, and (3) Folate as a homing molecule targeting FR-expressing cancer cells.
  • More importantly, we found that incorporating a short peptide sequence considerably improved the delivery efficiency of the probe--a process we attributed to a possible peptide-based pharmacomodulation--as was demonstrated by a 50-fold reduction in PPF accumulation in liver and spleen when compared to a peptide-lacking probe (Pyro-K-Folate, PKF).
  • This approach could potentially be generalized to improve the delivery efficiency of other targeted molecular imaging and photodynamic therapy agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Chem Soc. 2004 Sep 22;126(37):11450-1 [15366886.001]
  • [Cites] Expert Opin Drug Deliv. 2006 May;3(3):311-24 [16640493.001]
  • [Cites] Photochem Photobiol. 1987 Jun;45(6):879-89 [2957705.001]
  • [Cites] Br J Cancer. 1989 Mar;59(3):366-70 [2930700.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):87-93 [9002244.001]
  • [Cites] Bioconjug Chem. 1999 Nov-Dec;10(6):982-92 [10563767.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Photochem Photobiol. 2000 Jul;72(1):94-102 [10911733.001]
  • [Cites] Immunol Cell Biol. 2000 Aug;78(4):452-64 [10947873.001]
  • [Cites] Photochem Photobiol. 2000 Oct;72(4):533-40 [11045726.001]
  • [Cites] J Photochem Photobiol B. 2002 Mar;66(2):89-106 [11897509.001]
  • [Cites] Photochem Photobiol. 2002 Jun;75(6):644-51 [12081327.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Sep 13;54(5):675-93 [12204598.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1806-13 [12702566.001]
  • [Cites] Bioconjug Chem. 2003 May-Jun;14(3):539-45 [12757377.001]
  • [Cites] Radiology. 2003 Jul;228(1):29-35 [12832573.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7986-94 [14633731.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Jan 13;56(1):53-76 [14706445.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1099-109 [15094209.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1205-17 [15094216.001]
  • [Cites] Arch Ophthalmol. 2004 Jul;122(7):1002-11 [15249365.001]
  • [Cites] Biochemistry. 2004 Aug 31;43(34):10918-29 [15323552.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S146-56 [9806617.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1620-30 [15523091.001]
  • [Cites] J Med Chem. 2005 Jan 27;48(2):357-9 [15658849.001]
  • [Cites] Bioconjug Chem. 2005 Mar-Apr;16(2):429-37 [15769098.001]
  • [Cites] Bioorg Med Chem. 2005 Apr 15;13(8):2799-808 [15781391.001]
  • [Cites] Biochim Biophys Acta. 2005 May 15;1669(1):69-74 [15843001.001]
  • [Cites] Curr Pharm Biotechnol. 2005 Apr;6(2):131-50 [15853692.001]
  • [Cites] J Microsc. 2005 May;218(Pt 2):133-47 [15857375.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5317-24 [15958579.001]
  • [Cites] J Pharm Sci. 2005 Oct;94(10):2135-46 [16136558.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41203 [16178627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17757-62 [16306263.001]
  • [Cites] J Am Chem Soc. 2006 Feb 15;128(6):2115-20 [16464114.001]
  • [Cites] J Med Chem. 2006 Feb 23;49(4):1364-72 [16480271.001]
  • [Cites] Lasers Surg Med. 2004;35(3):181-90 [15389738.001]
  • (PMID = 17298029.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA105008-05; United States / NCI NIH HHS / CA / R01 CA135273; United States / NCI NIH HHS / CA / U54 CA105008; United States / NCI NIH HHS / CA / U54 CA105008-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Carrier Proteins; 0 / Fluorenes; 0 / Folate Receptors, GPI-Anchored; 0 / N(alpha)-fluorenylmethyloxycarbonylamino acids; 0 / Peptide Fragments; 0 / Receptors, Cell Surface; 1406-65-1 / Chlorophyll; 24533-72-0 / pyropheophorbide a; 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ NIHMS60164; NLM/ PMC2535810
  •  go-up   go-down


Advertisement
4. Jyonouchi H, Sun S, Iijima K, Gross MD: Antitumor activity of astaxanthin and its mode of action. Nutr Cancer; 2000;36(1):59-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we determined the effects of dietary astaxanthin on tumor growth and tumor immunity against transplantable methylcholanthrene-induced fibrosarcoma (Meth-A tumor) cells.
  • BALB/c mice were fed astaxanthin (0.02%, 40 micrograms/kg body wt/day in a beadlet form) mixed in a chemically defined diet starting zero, one, and three weeks before subcutaneous inoculation with tumor cells (3 x 10(5) cells, 2 times the minimal tumorigenic dose).
  • We also determined cytotoxic T lymphocyte (CTL) activity and interferon-gamma (IFN-gamma) production by tumor-draining lymph node (TDLN) and spleen cells by restimulating cells with Meth-A tumor cells in culture.
  • This antitumor activity was paralleled with higher CTL activity and IFN-gamma production by TDLN and spleen cells in the astaxanthin-fed mice.
  • When the astaxanthin-supplemented diet was started at the same time as tumor inoculation, none of these parameters were altered by dietary astaxanthin, except IFN-gamma production by spleen cells.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / immunology. beta Carotene / analogs & derivatives
  • [MeSH-minor] Animals. Antigens, Neoplasm / immunology. Diet. Female. Fibrosarcoma / chemically induced. Fibrosarcoma / drug therapy. Fibrosarcoma / immunology. Fibrosarcoma / pathology. Immunity, Cellular. Interferon-gamma / biosynthesis. Lymph Nodes / immunology. Lymph Nodes / metabolism. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / immunology. Mammary Neoplasms, Experimental / pathology. Methylcholanthrene. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Spleen / immunology. Spleen / metabolism. T-Lymphocytes, Cytotoxic / immunology. Xanthophylls

  • Hazardous Substances Data Bank. ASTAXANTHINE .
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10798217.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, Neoplasm; 0 / Xanthophylls; 01YAE03M7J / beta Carotene; 56-49-5 / Methylcholanthrene; 82115-62-6 / Interferon-gamma; 8XPW32PR7I / astaxanthine
  •  go-up   go-down


6. Xiang J, Tang J, Song C, Yang Z, Hirst DG, Zheng QJ, Li G: Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy; 2009;11(5):516-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma.
  • BACKGROUND AIMS: Cell-based gene therapy is an alternative to viral and non-viral gene therapy.
  • Emerging evidence suggests that mesenchymal stem cells (MSC) are able to migrate to sites of tissue injury and have immunosuppressive properties that may be useful in targeted gene therapy for sustained specific tissue engraftment.
  • ) 1x10(6) MSC, isolated from green fluorescent protein (GFP) transgenic rats, into Rif-1 fibrosarcoma-bearing C3H/HeN mice.
  • RESULTS: We observed that xenogenic MSC selectively migrated to the tumor site, proliferated and expressed the exogenous gene in subcutaneous fibrosarcoma transplants.
  • No MSC distribution was detected in other organs, such as the liver, spleen, colon and kidney.
  • We further showed that the FGF2/FGFR pathways may play a role in the directional movement of MSC to the Rif-1 fibrosarcoma.
  • We performed in vitro co-culture and in vivo tumor growth analysis, showing that MSC did not affect the proliferation of Rif-1 cells and fibrosarcoma growth compared with an untreated control group.
  • Finally, we demonstrated that the xenogenic MSC stably expressing inducible nitric oxide synthase (iNOS) protein transferred by a lentivirus-based system had a significant inhibitory effect on the growth of Rif-1 tumors compared with MSC alone and the non-treatment control group.
  • MSC may be used as a target gene delivery vehicle for the treatment of fibrosarcoma and other tumors.
  • [MeSH-major] Fibrosarcoma / genetics. Fibrosarcoma / therapy. Genetic Therapy. Mesenchymal Stromal Cells / cytology
  • [MeSH-minor] Animals. Cell Line. Cell Movement / drug effects. Cell Proliferation / drug effects. Fibroblast Growth Factor 2 / pharmacology. Green Fluorescent Proteins / metabolism. Humans. Mesenchymal Stem Cell Transplantation. Mice. Neoplasm Transplantation. Nitric Oxide Synthase Type II / metabolism. Rats. Subcutaneous Tissue / drug effects. Subcutaneous Tissue / pathology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562576.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2; 147336-22-9 / Green Fluorescent Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


7. Uekusa Y, Yu WG, Mukai T, Gao P, Yamaguchi N, Murai M, Matsushima K, Obika S, Imanishi T, Higashibata Y, Nomura S, Kitamura Y, Fujiwara H, Hamaoka T: A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res; 2002 Jul 1;62(13):3751-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice.
  • Interleukin (IL) 12 treatment in the CSA1M and OV-HM, but not in Meth A tumor models,induces tumor regression that is associated with T-cell migration to tumor sites.Here, we investigated the role of the CC chemokine receptor (CCR)5 in T-cell migration induced after IL-12 treatment.
  • In the two IL-12-responsive tumor models (CSA1M and OV-HM), IL-12 treatment up-regulated the mRNA expression of CCR5 in splenic T cells as well as ligands for CCR5, such as macrophage inflammatory protein (MIP) 1alpha and MIP-1beta in tumor masses.
  • In contrast, the expression of CCR5 in spleens and MIP-1alpha/MIP-1beta in tumor masses was marginally induced before and even after IL-12 treatment in the Meth A model in which T-cell migration is not observed.
  • Namely, although splenic T cells prepared from IL-12-treated CSA1M or OV-HM-bearing mice migrated into the corresponding tumor masses in recipient mice, the migration was inhibited when donor T cells were treated with anti-CCR5 antibody before the injection.
  • These results indicate a critical role for CCR5 in the induction of T-cell migration to tumor sites after IL-12 treatment.
  • [MeSH-minor] Amides / pharmacology. Animals. CCR5 Receptor Antagonists. Cell Movement / drug effects. Cell Movement / immunology. Chemokine CCL3. Chemokine CCL4. Female. Fibrosarcoma / chemically induced. Fibrosarcoma / drug therapy. Fibrosarcoma / immunology. Humans. Lymphocytes, Tumor-Infiltrating / cytology. Lymphocytes, Tumor-Infiltrating / immunology. Macrophage Inflammatory Proteins / biosynthesis. Macrophage Inflammatory Proteins / genetics. Macrophage Inflammatory Proteins / immunology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C3H. Mice, Inbred C57BL. Quaternary Ammonium Compounds / pharmacology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Spleen / cytology. Spleen / immunology. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12097285.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / CCR5 Receptor Antagonists; 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Macrophage Inflammatory Proteins; 0 / Quaternary Ammonium Compounds; 0 / RNA, Messenger; 0 / Receptors, CCR5; 187348-17-0 / Interleukin-12; 229005-80-5 / TAK 779
  •  go-up   go-down


8. Mushiake H, Tsunoda T, Nukatsuka M, Shimao K, Fukushima M, Tahara H: Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother; 2005 Feb;54(2):120-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we demonstrated that chemoimmunotherapy using S-1, a novel oral fluoropyrimidine anticancer drug, combined with lentinan (LNT), a beta (1 --> 3) glucan, was effective in vivo, and we clarified the augmentation of the function of dendritic cells (DCs) in vivo and in vitro.
  • The survival period of Colon-26-bearing mice treated with S-1 + LNT was significantly more prolonged than that of mice treated with S-1 alone (P < 0.05).
  • On the other hand, LNT did not prolong the survival period when combined with S-1 in Colon-26-bearing athymic mice.
  • The frequency of CD86+ DCs infiltrated into Colon-26 was increased in mice treated with S-1 + LNT, and splenic DCs harvested from mice treated with S-1 + LNT showed more potent T-cell proliferation activity than that of DCs from mice treated with S-1 alone (P < 0.05).
  • Furthermore, the activity of cytotoxic T lymphocytes (CTLs) in splenocytes of S-1 + LNT-treated mice was specific and more potent than that of CTLs from mice treated with S-1 alone (P < 0.05).
  • We demonstrated that DCs might play an important role in chemotherapy, and the combination therapy of S-1 and LNT presents a promising chemoimmunotherapy, which might lead to better survival for cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Dendritic Cells / metabolism. Immunotherapy, Adoptive. Neoplasms, Experimental / immunology
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / prevention & control. Adenocarcinoma / therapy. Animals. Colorectal Neoplasms / immunology. Colorectal Neoplasms / prevention & control. Colorectal Neoplasms / therapy. Combined Modality Therapy. Drug Combinations. Fibrosarcoma / immunology. Fibrosarcoma / prevention & control. Fibrosarcoma / therapy. Lentinan / administration & dosage. Lung Neoplasms / immunology. Lung Neoplasms / prevention & control. Lung Neoplasms / therapy. Lymphoma / immunology. Lymphoma / prevention & control. Lymphoma / therapy. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Nude. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Rats. Rats, Inbred Strains. Spleen / immunology. Survival Rate. T-Lymphocytes, Cytotoxic / metabolism. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592717.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 37339-90-5 / Lentinan; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


9. Voronov E, Reich E, Dotan S, Dransh P, Cohen I, Huszar M, Fogel M, Kleinman HK, White RM, Apte RN: Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential. J Immunotoxicol; 2010 Mar;7(1):27-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For this purpose, we have used 3-MCA-induced fibrosarcoma cell lines from IL-1 knockout (KO) versus control mice.
  • We could not detect differences in cell surface markers related to immunogenicity, such as MHC Class I, co-stimulatory, or adhesion molecules between both types of cells.
  • However, more T-cells were observed at the inoculation site of tumor cells devoid of IL-1 and more pronounced parameters related to anti-tumor immunity were observed in the spleen (IL-12 and IFNgamma) of these mice, compared to mice bearing tumors derived from control mice, where host-derived IL-1 is present.
  • This suggests that manipulation of IL-1 could be useful in anti-tumor therapy, by reducing invasiveness and promoting immunity against the malignant cells.
  • [MeSH-major] Fibrosarcoma / immunology. Interleukin-1 / immunology. Neoplasm Invasiveness / immunology. Neoplasm Transplantation / immunology. Sarcoma, Experimental / immunology
  • [MeSH-minor] Animals. Aorta, Thoracic / drug effects. Cell Line, Tumor. Chick Embryo. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. Endothelial Cells / drug effects. Female. Methylcholanthrene / pharmacology. Mice. Mice, Inbred C57BL. Mice, Knockout. Neovascularization, Pathologic / immunology. Spleen / drug effects. Spleen / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001788.001).
  • [ISSN] 1547-6901
  • [Journal-full-title] Journal of immunotoxicology
  • [ISO-abbreviation] J Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / Interleukin-1; 56-49-5 / Methylcholanthrene
  •  go-up   go-down


10. Molla Hassan AT, Hassan ZM, Moazzeni SM, Mostafaie A, Shahabi S, Ebtekar M, Hashemi SM: Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice. Int Immunopharmacol; 2009 Nov;9(12):1381-6
Hazardous Substances Data Bank. NALOXONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we used BALB/c mouse model of fibrosarcoma tumor and analyzed the tumor size, splenocyte proliferation, spleen and tumor-infiltrated lymphocytes.
  • Tumor and spleen CD4+CD25+Foxp3+ regulatory T lymphocytes, cytotoxic activity of the splenocytes, IFN-gamma and IL-4 secretion were assessed to describe the anti-tumor immune response.
  • Our findings showed that co-administration of gp96 and naloxone has resulted in a significant reduction in CD4+CD25+Foxp3+ regulatory T cells in the spleen.
  • [MeSH-major] Cytotoxicity, Immunologic / drug effects. Fibrosarcoma / drug therapy. Naloxone / administration & dosage. Narcotic Antagonists / administration & dosage. Spleen / drug effects. T-Lymphocytes, Regulatory / drug effects
  • [MeSH-minor] Animals. Antigens, CD4. Antigens, Neoplasm / immunology. Antigens, Neoplasm / isolation & purification. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Forkhead Transcription Factors. Interferon-gamma / secretion. Interleukin-2 Receptor alpha Subunit. Interleukin-4 / secretion. Lymphocytes, Tumor-Infiltrating / drug effects. Lymphocytes, Tumor-Infiltrating / immunology. Lymphocytes, Tumor-Infiltrating / pathology. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706340.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, Neoplasm; 0 / Forkhead Transcription Factors; 0 / Foxp3 protein, mouse; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Narcotic Antagonists; 0 / sarcoma glycoprotein gp96 rejection antigens; 207137-56-2 / Interleukin-4; 36B82AMQ7N / Naloxone; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


11. Cecic I, Stott B, Korbelik M: Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int Immunopharmacol; 2006 Aug;6(8):1259-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy.
  • Photodynamic therapy (PDT) inflicts tumor tissue injury that is experienced by the host as a local trauma.
  • Mouse FsaR fibrosarcoma model was used for investigating photodynamic therapy (PDT)-induced neutrophilia and its link to the acute phase response.
  • The rise in serum levels of complement C3 protein, which is an acute phase reactant and a principal mediator of tumor PDT-induced neutrophilia, occurred at the post PDT time period when the neutrophilia was largely resolved.
  • However, the activation of complement system (assessed by the standard erythrocyte hemolysis assay) peaked already at 6 h after PDT and correlated with the time kinetics of PDT-induced neutrophilia.
  • [MeSH-major] Acute-Phase Reaction / immunology. Fibrosarcoma / drug therapy. Neoplasms, Experimental / drug therapy. Neutrophils / drug effects. Photochemotherapy / adverse effects
  • [MeSH-minor] Adrenalectomy. Animals. Bone Marrow / drug effects. Bone Marrow / immunology. Complement Activation / drug effects. Complement Activation / immunology. Complement C3 / metabolism. Dihematoporphyrin Ether / administration & dosage. Dihematoporphyrin Ether / therapeutic use. Liver / drug effects. Liver / immunology. Lung / drug effects. Lung / immunology. Mice. Mice, Inbred C3H. Mice, Inbred Strains. Neutropenia / blood. Neutropenia / etiology. Neutropenia / immunology. Spleen / drug effects. Spleen / immunology. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782538.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Complement C3; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


12. Kubota N, Kojima T, Naruse T: Effect of hemostatics used during operations for digestive organ on cancer cells present in the peritoneal cavity. Cancer Biother Radiopharm; 2000 Feb;15(1):47-52
Hazardous Substances Data Bank. GELATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated effects of hemostatics used during operations for digestive organ on cancer cells present in the peritoneal cavity using BALB/c mice inoculated with Meth A tumor cells (fibrosarcoma) intraperitoneally (i.p.) and C3H/He mice inoculated with MH134 tumor cell (hepatic cell carcinoma) i.p.
  • Proliferation of Meth A tumor cells were not affected by the treatment.
  • Effect of liquid form gelatin on phytohemagglutinin (PHA)-stimulated spleen cells as a benign counter-part of RL male 1 tumor cells (T cell lymphoma) was examined.
  • Liquid form gelatin (15 mg/ml) did not suppress 3H-TdR uptake by PHA-stimulated spleen cells.
  • [MeSH-major] Collagen / therapeutic use. Digestive System Surgical Procedures. Fibrin Tissue Adhesive / therapeutic use. Gelatin / therapeutic use. Hemostatics / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Liver Neoplasms, Experimental / drug therapy. Liver Neoplasms, Experimental / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C3H. Peritoneal Cavity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10740652.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Fibrin Tissue Adhesive; 0 / Hemostatics; 9000-70-8 / Gelatin; 9007-34-5 / Collagen
  •  go-up   go-down


13. Ohe G, Okamoto M, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Uyama K, Bando T, Yoshida H, Sakai T, Himeno K, Sato M, Ohkubo S: Th1-cytokine induction and anti-tumor effect of 55 kDa protein isolated from Aeginetia indica L., a parasitic plant. Cancer Immunol Immunother; 2001 Jul;50(5):251-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro re-stimulation with AILb-A of splenocytes derived from AILb-A-primed mice also selectively induced Th1-type cytokines and antigen-specific killer cell activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Cytokines / biosynthesis. Neoplasms, Experimental / drug therapy. Th1 Cells / immunology
  • [MeSH-minor] Animals. Antibodies / immunology. Cells, Cultured. Cytotoxicity Tests, Immunologic. Female. Fibrosarcoma / immunology. Fibrosarcoma / therapy. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Plant Proteins / isolation & purification. Plant Proteins / pharmacology. Spleen / immunology. Survival Rate. Th2 Cells / immunology. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11499808.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antineoplastic Agents, Phytogenic; 0 / Cytokines; 0 / Plant Proteins
  •  go-up   go-down


14. Sovcikova A, Tulinska J, Chalupa I, Liskova A, Kuricova M, Horvathova M, Seemannovaa Z, Horakova K: Immunotoxic and cancerostatic effects of ethyl-4-isothiocyanatobutanoate in female Lewis rats with implanted fibrosarcoma. Int Immunopharmacol; 2002 Nov;2(12):1681-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotoxic and cancerostatic effects of ethyl-4-isothiocyanatobutanoate in female Lewis rats with implanted fibrosarcoma.
  • Immunotoxic and canocerostatic effects of E-41B in female inbred Lewis rats implanted with experimental fibrosarcoma BP6-TU2 was evaluated in this study.
  • On day 5 after subcutaneous application of tumor cells, animals started to be treated intraperitoneally three times a week with two different doses of E-41B: 28 and 35 mg/kg/day during 28 days.
  • Administrating of E-41B resulted in suppression of thymus, popliteal lymph node, spleen weight and spleen cellularity.
  • Immune assays--the phagocytic activity of polymorphonuclear leukocytes (PMN) and monocytes, primary antibody response and in vitro proliferative activity of spleen lymphocytes (LY) to mitogens were not significantly affected by E-41B treatment E-41B moderately decreased tumor weights, but this decrease was not statistically significant in comparison with DMSO-exposed rats with tumors.
  • The fibrosarcoma implantation itself increased significantly spleen weight and changed hematological parameters (decreased HB, increased mean cell volume of ERY, increased leukocyte count, increased % PMN, decreased % LY, decreased % EO).
  • Our findings indicate that administration of E-41B displayed hematoxic effect in rats implanted with fibrosarcoma.
  • Immunotoxic effect was shown as decreased lymphoid organ weight and spleen cytotoxicity although function of immune cells was not impaired.
  • [MeSH-major] Butyrates / immunology. Butyrates / pharmacology. Fibrosarcoma / drug therapy. Isothiocyanates / immunology. Isothiocyanates / pharmacology. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / adverse effects. Antineoplastic Agents / immunology. Antineoplastic Agents / pharmacology. B-Lymphocytes / cytology. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. Body Weight / drug effects. Dose-Response Relationship, Drug. Female. Leukocytes / cytology. Leukocytes / drug effects. Leukocytes / immunology. Organ Size / drug effects. Phagocytosis / drug effects. Rats. Rats, Inbred Lew. Spleen / cytology. Spleen / drug effects. Spleen / immunology. T-Lymphocytes / cytology. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12469942.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Butyrates; 0 / Isothiocyanates; 17126-65-7 / ethyl 4-isothiocyanatobutanoate
  •  go-up   go-down


15. Imani Fooladi AA, Sattari M, Reza Nourani M: Synergistic effects between Staphylococcal enterotoxin type B and Monophosphoryl lipid A against mouse fibrosarcoma. J BUON; 2010 Apr-Jun;15(2):340-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic effects between Staphylococcal enterotoxin type B and Monophosphoryl lipid A against mouse fibrosarcoma.
  • We investigated the possibility of the therapeutic application of SEB+ MPL in mice with fibrosarcoma.
  • METHODS: The antitumor effect of SEB+MPL, SEB and MPL in mice with inoculated fibrosarcoma tumor (WEHI-164) was examined by intravenous (i.v.) and intratumoral (i.t.) injection and the sizes of the inoculated tumors, IFN-gamma production, and CD4(+)/CD8(+) T cell infiltration were determined.
  • A significantly higher frequency of necrosis in tumor tissues was also observed in mice in the i.v. (SEB+ MPL)-injected group in comparison with other groups (p < 0.009).
  • They also suggest that tumor cell death by synergistic effect of one of the strongest bacterial superantigens (SEB) with monophosphoryl lipid A and SEB+MPL may be a good option for use as a novel therapy in patients with fibrosarcoma.
  • [MeSH-major] Enterotoxins / therapeutic use. Fibrosarcoma / drug therapy. Lipid A / analogs & derivatives
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Animals. Cell Line, Tumor. Female. Flow Cytometry. Interferon-gamma / biosynthesis. Interleukin-2 / biosynthesis. Mice. Mice, Inbred BALB C. Spleen / immunology. Superantigens / therapeutic use. T-Lymphocyte Subsets / cytology. T-Lymphocyte Subsets / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658733.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Enterotoxins; 0 / Interleukin-2; 0 / Lipid A; 0 / Superantigens; 39424-53-8 / enterotoxin B, staphylococcal; 82115-62-6 / Interferon-gamma; MWC0ET1L2P / monophosphoryl lipid A
  •  go-up   go-down


16. Okamoto M, Ohe G, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Ahmed SU, Yoshida H, Moriya Y, Saito M, Sato M: Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother; 2001 Oct;50(8):408-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that OK-PSA is a potent inducer of Th1-type cytokines in human peripheral blood mononuclear cells in vitro.
  • It was found that OK-PSA induced Th1-type cytokines [IFN-gamma, tumor necrosis factor-alpha, interleukin (IL)-2, IL-12 and IL-18] in BALB/c mice bearing Meth-A tumor and caused a marked anti-tumor effect.
  • Although it was suggested by an in vitro study. using spleen cells derived from the animals, that IL-18 plays the greatest role in the induction of the Th1-dominant state and tumor cell killing induced by OK-PSA, the in vivo experiments demonstrated that both IL-12 and IL-18 are essential in the anti-tumor effect exhibited by OK-PSA.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents / therapeutic use. Lipopolysaccharides / therapeutic use. Streptococcus pyogenes / immunology. Teichoic Acids / therapeutic use. Th1 Cells / drug effects
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antigens, CD95 / physiology. Apoptosis. Chromatography, Affinity. Drug Screening Assays, Antitumor. Fas Ligand Protein. Female. Fibrosarcoma / chemically induced. Fibrosarcoma / immunology. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Interleukin-12 / antagonists & inhibitors. Interleukin-12 / physiology. Interleukin-18 / antagonists & inhibitors. Interleukin-18 / physiology. Killer Cells, Natural / immunology. Lymphokines / blood. Lymphokines / secretion. Lymphoma / immunology. Lymphoma / pathology. Lymphoma / therapy. Lymphoma / virology. Membrane Glycoproteins / physiology. Mice. Mice, Inbred BALB C. Moloney murine leukemia virus. Neoplasm Transplantation. Penicillin G / pharmacology. Perforin. Picibanil / chemistry. Pore Forming Cytotoxic Proteins. Spleen / immunology. Spleen / pathology. Th2 Cells / drug effects. Th2 Cells / immunology. Th2 Cells / secretion. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PENICILLIN G .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11726135.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Interleukin-18; 0 / Lipopolysaccharides; 0 / Lymphokines; 0 / Membrane Glycoproteins; 0 / Pore Forming Cytotoxic Proteins; 0 / Teichoic Acids; 0 / Tumor Necrosis Factor-alpha; 126465-35-8 / Perforin; 187348-17-0 / Interleukin-12; 39325-01-4 / Picibanil; 56411-57-5 / lipoteichoic acid; Q42T66VG0C / Penicillin G
  •  go-up   go-down


17. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C: Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging; 2004 Jan;31(1):117-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor hypoxia, present in many human cancers, can lead to resistance to radiation and chemotherapy, is associated with a more aggressive tumor phenotype and is an independent prognostic factor of clinical outcome.
  • Region-of-interest analysis was performed as a function of time p.i. and indicated a tumor uptake of 5-10% (of total-body activity) for FMISO at 3-6 h p.i., and of ~17% for IAZG at 48 h p.i.
  • This was corroborated by biodistribution data in that the tumor-to-normal tissue (T/N, normal tissues of blood, heart, lung, liver, spleen, kidney, intestine, and muscle) activity ratios of IAZG at 24 h p.i. was 1.5-2 times higher than those of FMISO at 3 h p.i., with the exception of stomach.
  • [MeSH-major] Cell Hypoxia. Fibrosarcoma / diagnostic imaging. Fibrosarcoma / metabolism. Mammary Neoplasms, Animal / diagnostic imaging. Mammary Neoplasms, Animal / metabolism. Misonidazole / analogs & derivatives. Monosaccharides / pharmacokinetics. Nitroimidazoles / pharmacokinetics. Tomography, Emission-Computed / methods
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Metabolic Clearance Rate. Mice. Mice, Inbred C3H. Organ Specificity. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):229-37 [9572615.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):417-28 [8892467.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):467-72 [11586098.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50 [12692685.001]
  • [Cites] Radiat Res. 1988 Apr;114(1):64-76 [2895486.001]
  • [Cites] Med Phys. 1991 May-Jun;18(3):357-66 [1870476.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):337-44 [11216534.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1643-52 [11696633.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):177-83 [9935074.001]
  • [Cites] Appl Radiat Isot. 2001 Jan;54(1):73-80 [11144255.001]
  • [Cites] J Nucl Med. 2000 Feb;41(2):327-36 [10688119.001]
  • [Cites] Brain Res. 1995 Jul 10;685(1-2):91-8 [7583257.001]
  • [Cites] Semin Nucl Med. 2001 Oct;31(4):321-9 [11710774.001]
  • [Cites] Br J Cancer. 1955 Dec;9(4):539-49 [13304213.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1557-62 [8790218.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8 [12654432.001]
  • [Cites] Radiat Res. 2001 Jun;155(6):837-46 [11352767.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S209-12 [8763882.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):167-73 [12105986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82 [11240261.001]
  • [Cites] Pharm Res. 1994 Mar;11(3):466-9 [8008718.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17 (5):985-91 [2808061.001]
  • (PMID = 14523586.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA84596; United States / NCI NIH HHS / CA / R24 CA83084
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Monosaccharides; 0 / Nitroimidazoles; 0 / iodinated azomycin galactopyranoside; 082285VIDF / fluoromisonidazole; 8FE7LTN8XE / Misonidazole
  •  go-up   go-down


18. Hoffman RM: Tumor-targeting amino acid auxotrophic Salmonella typhimurium. Amino Acids; 2009 Sep;37(3):509-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have developed an effective bacterial cancer therapy strategy by targeting viable tumor tissue using Salmonella typhimurium auxotrophs that we have generated which grow in viable as well as necrotic areas of tumors.
  • However, the auxotrophy severely restricts growth of these bacteria in normal tissue.
  • The S. typhimurium A1-R mutant, which is auxotrophic for leu-arg and has high anti-tumor virulence, was developed in our laboratory.
  • A1-R was also targeted to both axillary lymph and popliteal lymph node metastasis of human pancreatic cancer and fibrosarcoma, respectively, as well as lung metastasis of the fibrosarcoma in nude mice.
  • The metastases were cured without the need of chemotherapy or any other treatment.
  • The primary pancreatic cancer regressed without additional chemotherapy or any other treatment.
  • The approach described here, where bacterial monotherapy effectively treats primary and metastatic tumors, is a significant improvement over previous bacterial tumor-therapy strategies that require combination with toxic chemotherapy.
  • Three promoter clones engineered in S. enterica typhimurium were identified to have enhanced expression in bacteria growing in tumors relative to those growing in the spleen.
  • The expression of therapeutics in Salmonella under the regulation of one or more promoters that are activated preferentially in tumors has the potential to improve the efficacy of Salmonella tumor therapy.
  • Exploitation of the tumor-killing capability of Salmonella has great promise for a new paradigm of cancer therapy.
  • [MeSH-major] Amino Acids / metabolism. Biological Therapy / methods. Neoplasms, Experimental / microbiology. Neoplasms, Experimental / therapy. Salmonella Infections, Animal. Salmonella typhimurium / growth & development

  • Hazardous Substances Data Bank. L-Leucine .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291366.001).
  • [ISSN] 1438-2199
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Amino Acids; 94ZLA3W45F / Arginine; GMW67QNF9C / Leucine
  • [Number-of-references] 30
  •  go-up   go-down


19. Su W, Zhang JH, Liu HW, Xiao G, Zhou XP, Sun JH, Liao CJ, Huang MX: [Treatment of mouse liver metastasis by intraportal injection of Adv-p53]. Zhonghua Zhong Liu Za Zhi; 2007 Nov;29(11):818-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of mouse liver metastasis by intraportal injection of Adv-p53].
  • OBJECTIVE: To investigate the anti-tumor effect of intraportal administration of Adv-p53 in the treatment of the liver metastasis in mice.
  • The spleen was transpositioned subcutaneously to enable the administration of Adv-p53 continually into the portal system.
  • CONCLUSION: Local administration of Adv-p53 into the portal system would be a useful strategy for the liver metastasis treatment.
  • [MeSH-major] Adenoviridae / genetics. Fibrosarcoma / pathology. Genetic Therapy. Liver Neoplasms, Experimental / therapy. Tumor Suppressor Protein p53 / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Recombinant Proteins / genetics. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396637.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


20. Ohmura Y, Matsunaga K, Motokawa I, Sakurai K, Ando T: Protective effects of a protein-bound polysaccharide, PSK, against Candida albicans infection in syngeneic tumor-bearing mice via Th1 cell functions. Cancer Biother Radiopharm; 2003 Oct;18(5):769-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In BALB/c mice that had received subcutaneous (sc) transplantation of fibrosarcoma Meth A, viable fungal counts were increased in the kidney and the mean survival period was shortened after challenge with C. albicans, compared with healthy mice.
  • The ratio of CD4-positive T cells in the spleen was decreased in noninfected tumor-bearing mice and the decrease was prevented by PSK, although in vitro anticandida activities of phagocytes were not significantly affected by tumor burden or PSK.
  • PSK enhanced the gene expression of interleukin (IL)-12 and IFN-gamma in the spleen of tumor-bearing mice inoculated with C. albicans.
  • Treatments with anti-IL-12 or anti-IFN-gamma antibody reduced the anti-infectious effects of PSK.
  • [MeSH-major] Candida albicans / immunology. Candidiasis / drug therapy. Candidiasis / immunology. Neoplasms / drug therapy. Proteoglycans / metabolism. Proteoglycans / therapeutic use. Th1 Cells / immunology
  • [MeSH-minor] Animals. Antibodies / immunology. Antibodies / pharmacology. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. Female. Interferon-gamma / antagonists & inhibitors. Interferon-gamma / genetics. Interferon-gamma / immunology. Interferon-gamma / metabolism. Interleukin-12 / antagonists & inhibitors. Interleukin-12 / genetics. Interleukin-12 / immunology. Interleukin-4 / metabolism. Mice. Mice, Inbred BALB C. Neoplasm Transplantation / immunology. Spleen / drug effects. Spleen / immunology. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14629825.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Proteoglycans; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 66455-27-4 / krestin; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


21. Sun XY, Zheng YP, Lin DH, Zhang H, Zhao F, Yuan CS: Potential anti-cancer activities of Furanodiene, a Sesquiterpene from Curcuma wenyujin. Am J Chin Med; 2009;37(3):589-96
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Curcuma. Drugs, Chinese Herbal / pharmacology. Furans / pharmacology. Heterocyclic Compounds, 2-Ring / pharmacology. Sesquiterpenes / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma. Animals. Breast Neoplasms. Carcinoma, Hepatocellular. Cell Division / drug effects. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. HL-60 Cells. HeLa Cells. Humans. K562 Cells. Leukemia. Liver Neoplasms. Lung Neoplasms. Mice. Mice, Inbred Strains. Organ Size. Spleen / pathology. Thymus Gland / pathology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606517.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Furans; 0 / Heterocyclic Compounds, 2-Ring; 0 / Sesquiterpenes; 19912-61-9 / furanodiene
  •  go-up   go-down


22. Chiarella P, Vulcano M, Bruzzo J, Vermeulen M, Vanzulli S, Maglioco A, Camerano G, Palacios V, Fernández G, Brando RF, Isturiz MA, Dran GI, Bustuoabad OD, Ruggiero RA: Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother; 2008 May;57(5):701-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we demonstrate that the failure to achieve an efficient immunological treatment against an established strongly immunogenic murine fibrosarcoma was paralleled with the emergence of a state of immunological unresponsiveness (immunological eclipse) against tumor antigens observed when the tumor surpassed the critical size of 500 mm(3).
  • In turn, the onset of the immunological eclipse was coincidental with the onset of a systemic inflammatory condition characterized by a high number of circulating and splenic polymorphonucleated neutrophils (PMN) displaying activation and Gr1(+)Mac1(+) phenotype and an increasing serum concentration of the pro-inflammatory cytokines TNF-alpha, IL-1beta and IL-6 cytokines and C-reactive protein (CRP) and serum A amyloid (SAA) phase acute proteins.
  • Treatment of tumor-bearing mice with a single low dose (0.75 mg/kg) of the synthetic corticoid dexamethasone (DX) significantly reduced all the systemic inflammatory parameters and simultaneously reversed the immunological eclipse, as evidenced by the restoration of specific T-cell-dependent concomitant immunity, ability of spleen cells to transfer anti-tumor activity and recovery of T-cell signal transduction molecules.
  • Two other anti-inflammatory treatments by using indomethacin or dimeric TNF-alpha receptor, also partially reversed the immunological eclipse although the effect was not as striking as that observed with DX.
  • The two-step strategy of tumor immunotherapy that we present is based on the rationale that it is necessary to eliminate or ameliorate the immunological eclipse as a precondition to allow an otherwise ineffective anti-tumor immunological therapy to have a chance to be successful.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Dendritic Cells / transplantation. Immune Tolerance / drug effects. Immunotherapy / methods. Inflammation / drug therapy. Neoplasms, Experimental / therapy
  • [MeSH-minor] Animals. Blotting, Western. Cancer Vaccines / therapeutic use. Dexamethasone / therapeutic use. Female. Flow Cytometry. Male. Mice. Mice, Inbred BALB C

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962945.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cancer Vaccines; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down






Advertisement